Drug Transporter (DT) Information

General Information of DT
DT ID DTD0352
Gene Name SLC3A2
Protein Name Lymphocyte activation antigen 4F2
Gene ID
6520
UniProt ID
P08195
TCDB ID
8.A.9.2.2
3D Structure

Crystal Structure

Crystallisation Method: EM

PDB ID: 7CCS

Corresponding Chain: A

Sequence Length: 2-630

Detail: Struture Info

Synonyms Solute carrier family 3 member 2; 4F2 cell-surface antigen heavy chain; 4F2hc; 4F2 heavy chain antigen; Lymphocyte activation antigen 4F2 large subunit; 4F2; 4T2HC; CD98HC; MDU1; NACAE; SLC3A2
DT Family rBAT Transport Accessory Protein (rBAT) Family ;
Function This transporter is involved in sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan and involved in guiding and targeting of LAT1 and LAT2 to the plasma membrane. When associated with SLC7A6 or SLC7A7,it acts as an arginine/glutamine exchanger, following an antiport mechanism for amino acid transport, influencing arginine release in exchange for extracellular amino acids. It plays a role in nitric oxide synthesis in human umbilical vein endothelial cells (HUVECs) via transport of L-arginine. It is required for normal and neoplastic cell growth. When associated with SLC7A5/LAT1, it is also involved in the transport of L-DOPA across the blood-brain barrier, and that of thyroid hormones triiodothyronine (T3) and thyroxine (T4) across the cell membrane in tissues such as placenta. Involved in the uptake of methylmercury (MeHg) when administered as the L-cysteine or D,L-homocysteine complexes, and hence plays a role in metal ion homeostasis and toxicity. When associated with SLC7A5 or SLC7A8,it get involved in the cellular activity of small molecular weight nitrosothiols, via the stereoselective transport of L-nitrosocysteine (L-CNSO) across the transmembrane. Together with ICAM1, it regulates the transport activity LAT2 in polarized intestinal cells, by generating and delivering intracellular signals. When associated with SLC7A5, it plays an important role in transporting L-leucine from the circulating blood to the retina across the inner blood-retinal barrier. When associated with LAPTM4B, it recruits SLC3A2 and SLC7A5 to lysosomes to promote leucine uptake into these organelles and is required for mTORC1 activation.
Endogenous Substrate(s) Neutral L-amino acids
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT (VARIDT 1.0)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Clinical Trial Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Polyamine
 Phase 2 Drug Info Subjective cognitive decline MB21.0 [1]
References
1 Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.